Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation

American Journal of Transplantation

Volumn 8, Issue 4, 2008, Pages 803-810

  Serra, A L ^a,b   Braun, S C ^a   Starke, A ^b   Savoca, R ^c   Hersberger, M ^d   Russmann, S ^a   Corti, N ^a   Wuthrich R P ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Regional Hospital Aarau   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cinacalcet; Hypercalcemia; Hyperparathyrodism; Renal transplantation

Indexed keywords

AZATHIOPRINE; CALCIUM; CINACALCET; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; PHOSPHATE; PREDNISONE; TACROLIMUS;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CLINICAL ARTICLE; DRUG CLEARANCE; FEMALE; HUMAN; HYPERPARATHYROIDISM; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; PHARMACODYNAMICS; PHOSPHATE METABOLISM; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE; URINARY EXCRETION;

AREA UNDER CURVE; CALCITONIN; CALCIUM PHOSPHATES; CHOLECALCIFEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY TRANSPLANTATION; NAPHTHALENES; PARATHYROID HORMONE;

EID: 40449141435     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.02136.x     Document Type: Article

References (40)

1. Lobo PI, Cortez MS, Stevenson W, Pruett TL. Normocalcemic hyperparathyroidism associated with relatively low 1,25 vitamin D levels post-renal transplant can be successfully treated with oral calcitriol. Clin Transplant 1995 9 : 277 281.
2. Reinhardt W, Bartelworth H, Jockenhovel F et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 1998 13 : 436 442.
3. Julian BA, Quarles LD, Niemann KM. Musculoskeletal complications after renal transplantation: Pathogenesis and treatment. Am J Kidney Dis 1992 19 : 99 120.
4. Hernandez D, Rufino M, Bartolomei S et al. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. Kidney Int 2005 67 : 2015 2020.
5. Gwinner W, Suppa S, Mengel M et al. Early calcification of renal allografts detected by protocol biopsies: Causes and clinical implications. Am J Transplant 2005 5 : 1934 1941.
6. Apostolou T, Damianou L, Kotsiev V, Drakopoulos S, Hadjiconstantinou V. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet. Clin Nephrol 2006 65 : 374 377.
7. Apostolou T, Kollia K, Damianou L et al. Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet. Transplant Proc 2006 38 : 3514 3516.
8. El-Amm JM, Doshi MD, Singh A et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007 83 : 546 549.
9. Leca N, Laftavi M, Gundroo A et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant 2006 6 : 2391 2395.
10. Serra AL, Savoca R, Huber AR et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007 22 : 577 583.
11. Serra AL, Schwarz AA, Wick FH, Marti HP, Wuthrich RP. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005 20 : 1315 1319.
12. Srinivas TR, Schold JD, Womer KL et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006 1 : 323 326.
13. Szwarc I, Argiles A, Garrigue V et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006 82 : 675 680.
14. Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005 20 : 1311 1314.
15. Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2007 22 : 2362 2365.
16. Harris RZ, Padhi D, Marbury TC, Noveck RJ, Salfi M, Sullivan JT. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 2004 44 : 1070 1076.
17. Miller WG, Myers GL, Ashwood ER et al. Creatinine measurement: State of the art in accuracy and interlaboratory harmonization. Arch Pathol Lab Med 2005 129 : 297 304.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 130 : 461 470.
19. Bajpai M, Esmay J, Chi V, Hayashi M, Poppe L, Kumar G. In vitro metabolism and predicition of drug-drug interactions of the calcimimetic agent cinacalcet HCL. Drug Metab Rev 2005 37 : 124.
20. Harris RZ, Salfi M, Posvar E, Hoelscher D, Padhi D. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol 2007 63 : 159 163.
21. Harris RZ, Salfi M, Sullivan JT, Padhi D. Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. Clin Pharmacokinet 2007 46 : 495 501.
22. Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant 2004 4 : 1514 1522.
23. Sonneveld P, Schoester M, de Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma: Effect of cyclosporine on resistant tumor cells. J Clin Oncol 1994 12 : 1584 1591.
24. Treiber A, Schneiter R, Delahaye S, Clozel M. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J Pharmacol Exp Ther 2004 308 : 1121 1129.
25. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995 13 : 129 134.
26. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003 88 : 5644 5649.
27. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005 90 : 135 141.
28. Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003 63 : 248 254.
29. Goodman WG, Hladik GA, Turner SA et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002 13 : 1017 1024.
30. Chattopadhyay N, Cheng I, Rogers K et al. Identification and localization of extracellular Ca2+-sensing receptor in rat intestine. Am J Physiol 1998 274 : G122 130.
31. Nemeth EF, Heaton WH, Miller M et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004 308 : 627 635.
32. Bushinsky DA, Laplante K, Asplin JR. Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats. Kidney Int 2006 69 : 1586 1592.
33. Vezzoli G, Soldati L, Arcidiacono T et al. Urinary calcium is a determinant of bone mineral density in elderly men participating in the InCHIANTI study. Kidney Int 2005 67 : 2006 2014.
34. Haas HG, Dambacher MA, Guncaga J, Lauffenbruger T. Renal effects of calcitonin and parathyroid extract in man. Studies in hypoparathyroidism. J Clin Invest 1971 50 : 2689 2702.
35. Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. Q J Med 1981 50 : 473 481.
36. Pfister MF, Ruf I, Stange G et al. Parathyroid hormone leads to the lysosomal degradation of the renal type II Na/Pi cotransporter. Proc Natl Acad Sci U S A 1998 95 : 1909 1914.
37. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005 67 : 760 771.
38. Nagano N, Miyata S, Obana S et al. Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder. Nephron 2001 89 : 321 328.
39. Schwarz A, Rustien G, Merkel S, Radermacher J, Haller H. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant 2007 22 : 584 591.
40. Jespersen B, Randlov A, Abrahamsen J, Fogh-Andersen N, Kanstrup IL. Effects of PTH (1-34) on blood pressure, renal function, and hormones in essential hypertension: The altered pattern of reactivity may counteract raised blood pressure. Am J Hypertens 1997 10 : 1356 1367.